Impact of Rapid Exome Sequencing on Pediatric Patients With Cardiomyopathy and Acute Heart Failure

Rapid exome sequencing (rWES) — impact on acute clinical management

Rapid exome sequencing (rWES) is evaluated in pediatric patients with cardiomyopathy and acute heart failure. Rapid genetic diagnosis in this urgent setting enables identification of the underlying etiology, guides specific treatment (e.g., Pompe disease, metabolic cardiomyopathy), and informs decisions regarding ventricular assist devices or cardiac transplantation.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Pediatric cardiomyopathy is one of the strongest indications for urgent genetic diagnosis: identifying a metabolic etiology (Pompe disease, mitochondriopathy) or genetic syndrome can direct specific treatment and dramatically alter prognosis. This work documents the real-world impact of rWES in this setting — data needed to justify its integration into pediatric cardiac care pathways.

Clinical impact : 3/3 · Evidence strength : 2/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 0/1 → Total : 7/10